New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
10:07 EDTTGI, SIVB, IMGN, FDS, ACHN, SFM, PPL, HALO, SAM, GRA, SIGM, ITMN, HPQ, APIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Achillion (ACHN) upgraded to Buy from Neutral at UBS... Advanced Photonix (API) upgraded to Buy from Neutral at B. Riley... Boston Beer (SAM) upgraded to Outperform from Underperform at CLSA... FactSet (FDS) upgraded to Market Perform from Underperform at Raymond James... HP (HPQ) upgraded to Neutral from Sell at Goldman... Halozyme (HALO) upgraded to Buy from Neutral at UBS... ImmunoGen (IMGN) upgraded to Neutral from Sell at UBS... InterMune (ITMN) upgraded to Buy from Neutral at UBS... PPL Corp. (PPL) upgraded to Buy from Neutral at Ladenburg... SVB Financial (SIVB) upgraded at RBC Capital... Sigma Designs (SIGM) upgraded at Needham... Sprouts Farmers Markets (SFM) upgraded to Outperform from Neutral at Credit Suisse... Triumph Group (TGI) upgraded at Credit Suisse... W.R. Grace (GRA) upgraded to Outperform from Neutral at Macquarie.
News For ACHN;API;SAM;FDS;HPQ;HALO;IMGN;ITMN;PPL;SIVB;SIGM;SFM;TGI;GRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 19, 2015
16:40 EDTACHNAchillion up 7% following collaboration for HCV with Janssen
Subscribe for More Information
16:10 EDTACHNAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation – JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
16:02 EDTACHNAchillion trading halted, pending news
Subscribe for More Information
12:55 EDTHPQPC related stocks struggle after Morgan Stanley says PC turn won't come until Q3
Subscribe for More Information
12:12 EDTACHNOptions with increasing implied volatility: ACHN ACM
Subscribe for More Information
07:56 EDTACHNGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
06:36 EDTHPQHP sued by MicroTech for $16.5M for 'unfairly taking advantage'
In a lawsuit filed Monday with the United States District Court for the Northern District of California in San Francisco, Virginia technology company MicroTech accuses Hewlett Packard and the software maker it now owns, Autonomy, of unfairly taking advantage by refusing to return $16.5M in cash paid to Autonomy for software never delivered in a fashion where it could be re-sold. During a national telephonic press conference, Lanny J. Davis, a Washington, D.C. attorney advising MicroTech, described the core allegation in the breach of contract case filed against HP: "Regardless of whether HP was defrauded by Autonomy, or whether HP's over-payment for Autonomy was a product of a possible due diligence failure, in my opinion, HP is not entitled to keep both MicroTech's money AND Autonomy's software that MicroTech duly purchased," Davis said.
06:24 EDTHPQHP to sell controlling stake in H3C unit to Tsinghua Unigroup, Reuters reports
HP will sell its 51% stake in H3C, its China-based computing unit, to Tsinghua Unigroup, Reuters reports, citing comments from a spokesperson for the Chinese private-equity fund's parent company. Terms have not been disclosed, but the spokesperson says he believes the deal will be completed in the coming days. Reference Link
05:48 EDTACHNStocks with implied volatility movement; ACHN WETF
Subscribe for More Information
May 18, 2015
16:21 EDTACHNOn The Fly: Top stock stories for Monday
Stocks on Wall Street advanced in Monday trading, sending the Dow Jones Industrial Average and the S&P 500 to new all-time closing highs. The early part of the day saw the market move in a narrow range, but by early afternoon the market punched through its upper range and moved to session highs. The market drifted throughout the afternoon as the news flow was quiet and the trading volume remained light. ECONOMIC EVENTS: In the U.S., the National Association of Home Builders’ confidence index fell 2 points to a reading of 54 in May, missing expectations for a 1 point increase to a reading of 57. COMPANY NEWS: Shares of Apple (AAPL) advanced $1.47, or 1.14%, to $130.24 after noted investor Carl Icahn stated in an open letter to the company's CEO that he thinks other investors, analysts and the news media continue to misunderstand Apple and that its stock is "worth $240 today." Icahn urged Apple CEO Tim Cook to take advantage by launching a "much larger buyback" of the iPhone maker's shares. Separately, FBR Capital analysts Daniel Ives and James Moore wrote this morning in a note to investors that the Street is still underestimating Apple's growth outlook in China. The analysts believe that Apple's China revenue will exceed its revenue from the Americas in fiscal 2017... Endo International (ENDP) slid $4.53, or 5.31%, to $80.82 after the company agreed to pay $8B for privately held Par Pharmaceutical, which will roughly double Endo’s generics revenue and place its generics business among the top five as measured by U.S. sales. MAJOR MOVERS: Among the notable gainers was Ann Inc. (ANN), which surged $7.69, or 19.87%, to $46.40 after agreeing to be acquired by Ascena Retail Group (ASNA) for about $2.15B in cash and stock. Ascena, which agreed to pay $37.34 in cash and 0.68 of a share of its own common stock in exchange for each share of the parent of the Ann Taylor brand, slipped 14c, or 0.99%, to $14.07 after announcing the deal. Also higher was Achillion (ACHN), which rose $1.41, or 14.79%, to $10.98 after the company cancelled its presentation at the UBS Global Healthcare Conference. Conference cancellations often generate speculation as to whether a company is engaged in merger or acquisition talks. Among the noteworthy losers was Eleven Biotherapeutics (EBIO), which dropped $8.29, or 69.26%, to $3.68 after announcing the company’s Phase 3 study of its lead drug candidate, EBI-005, in moderate to severe dry eye disease did not meet either of its two co-primary endpoints. Also lower were shares of Weibo (WB), which fell 87c, or 5.24%, to $15.73 after the shares were downgraded to Hold from Buy at Summit Research. INDEXES: The Dow rose 26.32, or 0.14%, to 18,298.88, the Nasdaq gained 30.15, or 0.6%, to 5,078.44, and the S&P 500 added 6.47, or 0.3%, to 2,129.20.
16:16 EDTACHNGilead confirms plans to present tomorrow at UBS conference, Feuerstein reports
Subscribe for More Information
15:29 EDTACHNOptions with increasing volume
Options with increasing volume: ACHN PAGP CBG NI NGLS LEA OKS GTI WETF URBN
14:42 EDTACHNAchillion rises as conference cancellation adds fuel to M&A speculation
Subscribe for More Information
14:15 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
12:51 EDTACHNOn The Fly: Top stock stories at midday
Subscribe for More Information
11:40 EDTACHNAchillion jumps after conference presentation cancelled
Subscribe for More Information
09:20 EDTGRAW.R. Grace, Chevron JV to build catalysts plant in Lake Charles, LA
Subscribe for More Information
May 15, 2015
11:00 EDTHPQHewlett-Packard volatility elevated into Q2 and outlook
Subscribe for More Information
10:13 EDTSFMHigh option volume stocks
High option volume stocks: POST SFM GSVC HGG HUN PH JWN CAR ONTY LBTYA
07:40 EDTHPQHP split to be positive catalyst, says Deutsche Bank
Deutsche Bank believes HP's split will be a positive catalyst for shares this year. It views the stock as attractively priced ahead of the Q2 results on May 21 and says HP remains a top pick for 2015. Deutsche has a Buy rating on the name with a $45 price target.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use